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THE ROLE OF RETINALDEHYDE AND PPARGAMMA SIGNALING IN 
SYSTEMIC LUPUS ERYTHEMATOSUS 
 
SHI SU 
ABSTRACT 
 Systemic Lupus Erythematosus (SLE) is an autoimmune disease with chronic 
inflammation affecting multiple organ systems, as well as accelerated atherosclerosis as a 
major complication. Prior studies by our lab have shown beneficial effects of PPARγ 
agonists towards preventing SLE in two different mouse models: the well-established 
lupus mouse model, MRL.lpr, and the gld.apoE
-/-
 model of accelerated lupus and 
atherosclerosis. Retinaldehyde is a retinoic acid precursor that has recently been shown to 
inhibit PPARγ signaling in adipose tissue. We proposed that abnormal accumulation of 
retinaldehyde in lupus promotes autoimmunity by inhibition of PPARγ signaling. We 
measured the serum retinaldehyde levels in both lupus mouse models using reversed-
phase high-performance liquid chromatography. We also examined the mRNA 
expressions of genes involved in retinaldehyde metabolism and PPARγ signaling in white 
adipose tissues using real-time quantitative PCR. We observed a higher level of 
circulating retinaldehyde in the MRL.lpr mouse model on a chow diet. The circulating 
retinaldehyde levels in both gld.apoE
-/-
 and C57 increased when maintained on a high-
cholesterol Western diet. Within visceral and subcuntaneous adipose tissue, we saw 
several changes to expression of the genes responsible for retinaldehyde synthesis and 
catabolism, however further study is required to definitively assess the role of these 
genes. Importantly, the expression levels of genes involved in PPARγ signaling 
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decreased in the subcutaneous fat of gld.apoE
-/-
 mice on a Western diet. Our data suggest 
that retinaldehyde may play a role in SLE pathogenesis and could be a potential 
therapeutic target for SLE. 
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INTRODUCTION 
 
Systemic Lupus Erythematosus  
Systemic Lupus Erythematosus (SLE) is an autoimmune disorder that occurs most 
frequently in women of childbearing age (Bernatsky et al., 2007). The ratio of female and 
male lupus patients is greater than 8:1 between the ages of 15 to 50 (Kotzin, 1996). The 
estimated SLE prevalence ranges from about 81 to 103 per 100,000 individuals in the 
United States every year (Furst et al., 2013). SLE is characterized by the production of 
autoantibodies against intracellular antigens, with variable clinical features, including 
rashes, arthritis, nephritis, serositis, cerebritis, and a host of serological abnormalities, 
including abnormal serum anti-DNA and complement levels (Moser et al., 1998; 
Lightfoot & Hughes, 1976). The onset and development of SLE may be influenced by 
genetic and environmental factors, some of which include class II MHC genes, viral or 
bacterial infections, administration of exogenous hormones, chronic use of certain drugs, 
and impaired clearance of apoptotic cells (Kotzin, 1996; Baumann, 2002; Aprahamian, 
2004).  
Lupus mouse model 
The Fas system, including the Fas receptor and Fas ligand, is crucial in the 
immune system, especially against autoimmunity, as it eliminates pathogen-infected cells 
and potentially dangerous lymphocytes (Strasser et al., 2009).  FasL is a death factor that, 
when it binds to the Fas receptor, induces apoptosis (Nagata & Suda, 1995). Gld and lpr 
are mouse models with known mutations within genes encoding Fas ligand (FasL) and 
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Fas receptor, respectively (Nagata & Suda, 1995). Both gld and lpr are autosomal 
recessive mutations that lead to lymphoproliferation and autoimmunity (Cohen & 
Einsberg, 1991).  
As described by Cohen and Einsberg, the MRL.lpr mouse strain exhibits a 
proliferative glomerulonephritis, progressive enlargement of lymph nodes, and 
autoimmune disease in other organs. Purpuric lesions can occur on the ears and tail of the 
MRL.lpr mice. Since the lpr gene induces abnormal B-cell activation, a higher 
immunoglobulin level, particularly IgG, is observed in the serum. Manifestations of the 
lpr defect vary by genetic backgrounds. For instance, MRL.lpr develops the most severe 
lymphoproliferation and renal disease with the shortest life expectancy, whereas 
C57BL/6-lpr mice develop a more mild autoimmune disease (Cohen & Einsberg, 1991).  
Mice with a gld mutation share a similar phenotype to that of the lpr on the same 
background, suggesting that these two mutations affect the same pathways of lymphocyte 
differentiation (Cohen & Einsberg, 1991). The lupus-like phenotypes made the gld and 
lpr mice important mouse models to give insights to the immunopathology of lupus 
(Cohen & Einsberg, 1991). 
Atherosclerosis 
Atherosclerosis is a chronic inflammatory condition and a major cause of 
cardiovascular diseases, a type of disease that affects more than one third of American 
adults (Frostegard, 2013 & Go et al., 2013). A high concentration of cholesterol, 
especially low density lipoprotein cholesterol (LDL), leads to accumulations of lipid-rich 
plaques within the artery wall, forming atherosclerotic lesions (Ross, 1999 & Frostegard, 
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2013). The development of atherosclerotic lesions can lead to ischemia of the heart or 
brain, and plaque ruptures of the fibrous cap can trigger myocardial infarction and stroke 
(Ross, 1999 & Dutta et al., 2012). 
-Apolipoprotein E   
Apolipoprotein E (apoE) is an anti-atherogenic protein synthesized in the liver 
and by macrophages (Elshourbagy et al., 1985). The major function of apoE is to serve as 
a high affinity ligand for LDL receptors on the membrane, allowing uptake of 
atherogenic particles, such as chylomicrons and very low density lipoprotein remnants, 
from circulation (Jawien et al., 2004 & Imaizumi, 2011). Mice deficient in apoE have 
elevated total circulating cholesterol levels, and a reduction in anti-atherogenic high 
density lipoprotein (HDL) levels, compared to control mice (Plump et al., 1992). ApoE
-/- 
mice have been widely used as a mouse model for atherosclerosis studies as they develop 
extensive arterial lesions on a chow diet, which is markedly accelerated by high 
cholesterol Western diet (Plump et al., 1992 & Imaizumi, 2011). 
-Gld. apoE
-/-
mouse model 
Mice that harbor both the gld mutation and apoE deficiency were generated to 
study accelerated atherosclerosis in systemic lupus erythematosus. This model exhibits 
larger atherosclerotic lesion area compared with apoE
-/-
 mice, and increased 
lymphadenopathy, splenomegaly, and autoantibodies compared with gld mice due in part 
to impaired clearance of apoptotic bodies (Aprahamian et al., 2004). 
-Link between atherosclerosis and SLE 
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An increased risk of atherosclerosis is presented in lupus patients, and premature 
atherosclerosis has been recognized as the major cause of morbidity and mortality in SLE 
(McMahon & Hahn, 2007 & Nikpour et al., 2005). Patients with SLE have an estimated 
50-fold increased risk of myocardial infarction compared to non-SLE controls (McMahon 
& Hahn, 2007). 
Inflammation is an important factor in the initiation and progression of 
atherosclerosis (Ross, 1993). In SLE patients, the pathogenesis of atherosclerosis is 
largely contributed by the interplay of inflammation and immune mechanisms, which 
leads to increased levels of oxidized lipids (such as oxidized LDL and pro-inflammatory 
HDL) and up-regulation of adhesion molecules and cytokines (McMahon & Hahn, 2007). 
In addition, impaired clearance of apoptotic bodies has been shown to play a role in the 
progression of both atherosclerosis and SLE (Aprahamian et al., 2004). 
Retinaldehyde 
Vitamin A is an essential molecule obtained from the diet that plays a key role in 
immune function as an important modulator of TGF, which can suppress several 
cytokines involved in pro-inflammatory responses (Castellani et al., 2010; Berry & Noy, 
2012). Most of the functions of vitamin A are exerted by its active metabolites rather than 
the parental vitamin A molecule, retinol, due to the tightly regulated biological pathway 
(Berry & Noy, 2012). Once absorbed in the intestine, vitamin A is transported into blood 
stream and enters the liver, converting to retinol, which re-enters bloodstream bound to 
retinol binding protein (RBP) (Hall et al., 2011). After entering the cells, retinol is 
reversibly oxidized by alcohol dehydrogenase (ADH) into retinaldehyde, which is then 
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irreversibly metabolized into retinoic acid (RA) by rate-limiting regulating enzymes, 
retinal dehydrogenases (RALDH1, 2) (Hall et al., 2011 & Gudas, 2012). Therefore, 
retinaldehyde is an intermediate metabolite between vitamin A (retinol) and retinoic acid 
(Kim et al., 1992) (Fig. 1). Retinoic acid serves as a ligand for nuclear receptors such as 
the retinoic acid receptor (RAR) and the retinoid X-receptor (RXR) (Rudraraju et al., 
2014). Besides its biological role in the vision cycle, retinaldehyde has also been found to 
be present in rodent fat with the capacity of inhibiting adipogenesis and suppressing 
peroxisome proliferator-activated receptor gamma and RXR responses (Ziouzenkova et 
al., 2007).  
 
Figure 1: Retinaldehyde is an intermediate metabolite of vitamin A. 
Peroxisome proliferator-activated receptor-γ 
Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the 
PPAR subfamily of nuclear hormone receptors (Tontonoz & Spiegelman, 2008). PPARγ 
is involved in the control of lipid metabolism and inflammation and is expressed in the 
major cell types that make up atherosclerotic lesions, including macrophage foam cells, 
smooth muscle cells, lymphocytes, and endothelial cells (Ricote et al., 1998; Sueyoshi et 
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al., 2001). In vivo studies have shown that PPARγ strongly inhibits atherosclerotic lesion 
formation (Li et al., 2004). Several clinical studies also supported that PPARγ agonists 
improve atherosclerotic markers in human subjects (Brown & Plutzky, 2007). The 
activation of PPARγ induces CD36, a class B scavenger receptor that enhances the 
uptake of the oxidized LDL into cells, as well as adiponectin, a fat-specific hormone that 
exerts anti-inflammatory effects (Brown & Plutzky, 2007).  In addition, PPARγ 
activation is able to upregulate RALDH2, the enzyme responsible for converting 
retinaldehyde to retinoic acid (Szatmari et al., 2006). However, PPARγ activation is 
inhibited by the presence of retinaldehyde in fat (Ziouzenkova & Plutzky, 2008). 
Thiazolidinediones are PPARγ agonists used as anti-diabetic agents due to their ability to 
increase the insulin sensitivity of type 2 diabetes mellitus. Recently, thiazolidinediones 
have been shown to reduce autoantibody production, renal disease, and atherosclerosis in 
mouse models of SLE, by inducing adiponectin (Aprahamian, 2009, 2014). Taken 
together, these data demonstrate that activation of PPARγ provides benefits towards 
ameliorating disease, and inhibition of PPARγ is detrimental to disease progression. 
SLE and metabolic syndrome 
Several lines of clinical evidence suggest that SLE is also associated with an 
increased prevalence of the metabolic syndrome (MetS), which is defined as a 
combination of cardiovascular risk factors with increased insulin resistance and a high 
risk of developing type 2 diabetes (Parker et al., 2010). NZBWF1 lupus mice maintained 
on a high fat diet exhibit visceral obesity and peripheral vascular dysfunction (Gilbert & 
Ryan, 2011). It has also been demonstrated that metabolic dysfunction can occur in a 
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mouse strain susceptible to lupus, defined as impaired glucose tolerance (Gabriel et al., 
2012). These findings in mice extend to humans, demonstrated by clinical evidence 
showing that SLE is associated with an increased prevalence of the MetS (Parker & 
Bruce, 2013; Parker et al., 2013; Chung et al., 2007) 
Patients with MetS often present with central adiposity, a main contributor to 
insulin resistance (Parker & Bruce, 2013). Adiponectin is an adipose-derived protein that 
decreases with increasing adiposity and has been shown to increase insulin sensitivity 
(Yang & Chuang, 2006). Since low concentrations of adiponectin have been observed in 
patients with MetS, adiponectin is proposed by some researchers to be a possible link 
connecting MetS and SLE (Ryo et al., 2004; Matsuzawa et al., 2004; Parker & Bruce, 
2013). Therefore, it stands to reason that retinaldehyde and its role in PPARγ signaling 
could be crucial to the downregulation of adiponectin and progression of SLE. 
Summary and goals of the thesis 
In summary, since the activation of PPARγ signaling has been shown to have an 
effect on SLE prevention, and suppressed PPARγ signaling is presented in the mouse 
model lacking retinaldehyde catabolizing enzyme, we hypothesized that a high level of 
circulating retinaldehyde may play a role in SLE pathogenesis by inhibiting PPARγ 
signaling. Therefore, the goals of the thesis are: 
1. To assess the body composition of the MRL.lpr lupus mouse model on chow 
diet, and the gld.apoE
-/-
 mouse model of accelerated atherosclerosis and lupus 
on both chow diet and high-cholesterol Western diet, in comparison with their 
wild type controls (MRL and C57, respectively).  
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2. To develop a reliable assay using high performance liquid chromatography to 
quantify circulating retinaldehyde levels in our mouse cohorts. 
3. To measure the mRNA expression of genes involved in retinaldehyde 
metabolism, as well as PPARγ signaling, in two white adipose tissue depots 
from our mouse cohorts. 
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METHODS  
Animals and Diet 
We obtained female C57BL/6 (#000664) (wild type), MRL (#000486), and 
MRL.lpr mice (#000485) from Jackson Laboratories. The female gld.apoE-/- mice were 
originally generated by crossing gld and apoE-/- mice on a C57BL/6 background, and 
have been established as a mouse model of accelerated atherosclerosis and lupus 
(Aprahamian, 2004, 2009).  
Starting at 7 weeks of age, the wild type and gld.apoE-/- mice were maintained on 
a chow diet (Teklad Global 18% Protein Rodent Diet) (n=12 per genotype) or a high- 
cholesterol Western Diet (Harlan Adjusted Calories Diet, 42% from fat; TD.88137) 
(n=12 per genotype) for 12 weeks. The chow diet contained, as a percent of total 
kilocalories, 24% protein (crude protein), 18% total fat (ether extract) and 58% 
carbohydrate (calculated by subtracting neutral detergent fiber from total carbohydrate). 
The Western diet contained, as a percent of total kilocalories, 15.2% protein (casein plus 
additional DL-Methaionine), 42.0% total fat (andydrous milkfat plus cholesterol) and 
42.7% carbohydrate (sucrose plus corn starch). The animal experiments were performed 
under protocols approved by the Institutional Animal Care and Use Committee of Boston 
University School of Medicine. 
High Performance Liquid Chromatography (HPLC) 
-Retinaldehyde Oxime Standard 
Retinaldehyde (Rald) oxime standard was generated by reducing 100 µM all-trans 
retinal (Santa Cruz Biotechnology) with 1M hydroxylamine (Sigma H2391) and 25 µM 
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ethylenediaminetetraacetic acid (EDTA) in PBS under argon and protected from light for 
two hours at room temperature. 
-Serum Sample Preparation 
After euthanasia by CO2, blood was drawn from the mice by cardiac puncture. 
Plasma was separated by immediately centrifuging at 4000 rpm for 5 minutes at 4°C 
(Eppendorf, 5430R). Plasma (minimum of 250μL; maximum of 400μL) was added to a 
solution containing 1M hydroxylamine (Sigma H2391) and 25μM EDTA in methanol 
under argon and protected from light for two hours at room temperature. This allows the 
retinaldehyde in the blood to be converted to its oxime derivative, a more stable form of 
retinaldehyde, for HPLC analysis. The samples were stored at -80 °C until further 
processing.  
-HPLC Sample Preparation 
Before HPLC analysis, 10µl of 20 ng/µl Vitamin D2 solution was added to each 
serum sample, to serve as an internal standard for recovery calculation. After 1 hour at 
4°C in the dark, the retinaldehyde oxime was extracted from the prepared retinaldehyde 
oxime standard or serum samples by adding 4000µl Hexane and centrifuging at 1000xg 
for 3 minutes at 4°C (Sorvall RT6000B). The hexane extracts were evaporated under a 
gentle stream of nitrogen. The residues were reconstituted in 120µl acetonitrile and 
transferred to a 350µL Fused Insert MacroVial (Thermo Scientific) for HPLC analysis. 
-HPLC System 
The HPLC system (Agilent 1200 Series) included a quaternary pump (G1311A) 
operating at a flow of 1.0ml/min, a 3µm Pecosphere C-18 column (83X4.6mm, 
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PerkinElmer), a thermoregulated autosampler (G1329A), a column thermostat (G1316A), 
and a Diode Array Detector (G1315D). The mobile phase was composed of 60% 
acetonitrile, 39.9% water and 0.1% formic acid. Using a reverse-phase HPLC method, 
analytes were separated at 1ml/min with a linear gradient of acetonitrile:water:formic 
acid from 60%:39.9%:0.1% to 94.9%:5%:0.1% over a duration of 5 minutes. 
-Peak Identification, Quantification and Internal Standard Validation 
The analyte peaks were identified by retention times and UV spectra, according to 
those observed with the external standards, retinaldehyde oxime and vitamin D2, in each 
run. The serum retinaldehyde concentrations were quantified by using the standard curve 
of external retinaldehyde oxime standard, adjusted by the % recovery obtained from the 
added vitamin D2 standard. The vitamin D2 standard was validated by three test runs 
substituting mouse serum with 5mg/ml of Bovine Serum Albumin (BSA) (AmericanBio, 
Natick, MA) solution in water. All testing samples were run in triplicate.  
Tissue Collection 
Mice were euthanized using carbon dioxide at endpoint. The spleen, cervical 
lymph nodes, visceral fat, subcutaneous fat and heart were removed from the body, snap 
frozen in liquid nitrogen, and stored at -80 °C for RNA analysis and histology. The 
weights of the spleen and cervical lymph nodes, as well as total body weight were 
recorded. 
Reverse Transcriptase PCR (RT-PCR) and Quantitative Real Time PCR (qPCR) 
The spleen, lymph node, visceral fat and subcutaneous fat tissues from the mice 
were homogenized in QIAzol Lysis Reagent (for adipose tissues) (QIAGEN), or Buffer 
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RLT (for non-adipose tissues) (QIAGEN), using the Qiagen TissueLyzer II System. Total 
RNA was isolated using an RNeasy tissue kit (Qiagen) and assayed using a Nanodrop 
spectrophotometer (ThermoScientific, Wilmington, DE) to assess purity and 
concentration. RT-PCR was performed with 1 µg of RNA using the QuantiTect Reverse 
Transcription Kit (QIAGEN). Gene expression analysis was performed using T100™ 
Thermal Cycler (Bio-Rad). 2µL of diluted cDNA (diluted 1 10) generated from RT-PCR 
was then used as template for qPCR amplification using TaqMan® Real-Time PCR 
Master Mix (Life Technologies) in a total reaction volume of 20 µL. The Comparative Cт 
method (ΔΔCт) was employed in ViiA™ 7 Real-Time PCR System (Life Technologies) 
to determine relative fold changes in mRNA expression. GAPDH was used as the 
endogenous control. The mRNA expression of, ADH1, RALDH1, RALDH2, PPARγ, 
adiponectin, and CD36, were examined using TaqMan® expression assays. All samples 
were run in duplicate. 
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RESULTS 
 
Reference standards of HPLC developed using Bovine Serum Albumin.  
 Due to the within-run and between-run variations of the sample preparation prior 
to HPLC separation, it was important to establish a reliable internal standard in each 
sample. The Bovine Serum Albumin (BSA) solution shares a high physiological 
similarity with mouse serum samples (Hamidi & Zarei, 2009). Therefore, we used a BSA 
solution with a fixed concentration (5mg/ml) to test the recovery efficiencies of the 
internal vitamin D2 standard and the external oxime standard.    
 Our test runs showed that 1µmol of oxime standard has a retention time of 6.5min 
and a peak area around 200 units (Fig 2a). Varying concentrations of oxime solutions 
were evaluated by comparing to the oxime peak areas in mouse serum. The oxime area of 
mouse serum ranged from 100 to 300 units. Therefore, the oxime solution with a 
concentration of 0.1 µmol/µl was selected as an external standard as 10µl of the solution 
provided a peak area around 200 units. Vitamin D2 standard was added at a concentration 
of 200ng (10 µl of 20ng/ µl) and had a retention time of 17min and a peak area around 
450 units (Fig 2b). When mixed with BSA solution, the oxime standard has an average 
peak area around 110 units, and the vitamin D2 has an average peak area around 270 
units, showing a recovery rate of 55%, 59%, respectively. Based on the testing results, we 
were able to obtain a factor close to 1 for the recovery rate ratio of oxime and vitamin D2, 
indicating that the two compounds have similar yield and that vitamin D2 can be used as 
an internal standard. We identified the oxime peaks in the serum samples of our mouse 
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models using the retention time of the external oxime standard in each run (Fig 2c-f). We 
quantified the retinaldehyde concentrations in our serum samples based on the recovery 
rate ratio of oxime and vitamin D2.  
 
Figure 2: Chromatograms of oxime standard, vitamin D2 standard, and serum 
samples. Values in milliabsorbance units (mAU) of (a) oxime standard (at 325nm). (b) 
Vitamin D2 standard (at 265nm). Oxime peak in serum samples of (c) wild type mouse on 
Western diet; (d) gld.apoE
-/-
 mouse on Western diet; (e) MRL mouse; (f) MRL.lpr 
mouse.  
Analysis of MRL.lpr lupus mouse model 
Because lupus is an inflammatory disorder accompanied by a high oxidative 
stress state, we hypothesized that elevated retinaldehyde (Rald) levels might be present in 
SLE. The female MRL.lpr mouse develops severe lymphadenopathy and splenomegaly 
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and has an average lifespan of 17 weeks. MRl.lpr mice, and its control, MRL, were fed 
with chow diet. At 16 weeks of age, MRl.lpr mice showed no difference in body weight 
compared with their controls (Fig. 3a), but presented larger lymph nodes and spleens. 
Interestingly, the MRl.lpr mice displayed decreased weight of visceral and subcutaneous 
adipose depots (Fig. 3b-d).  
 
Figure 3: Body and organ weights of MRL.lpr mice. (a) Endpoint body weight. (b) 
Lymph node, (b) spleen, and (c) visceral (VFAT) and subcutaneous (SUBQ) adipose 
tissues were excised and weighed (n=8 per group; *, p< 0.05). 
To determine if retinaldehyde may be playing a role in lupus pathogenesis, we 
first measured circulating retinaldehyde levels. MRL.lpr mouse displayed increased 
serum retinaldehyde levels compared with the MRL control on a chow diet 
([Rald]=5.00 0.36, 3.78 0.24 nmol/μl, respectively) (Fig. 4).  
  
16 
 
Figure 4: Circulating retinaldehyde (Rald) is increased in MRL.lpr mice. Serum was 
collected and analyzed by HPLC from 16 week old mice maintained on a chow diet. 
(MRL, n=8; MRL.lpr, n=7; p<0.05). 
To examine a potential cause for the observed increase in retinaldehyde levels, 
mRNA expression levels were determined for genes involved in retinaldehyde synthesis 
and catabolism, alcohol dehydrogenase 1 (ADH1) and retinaldehyde dehydrogenase 1& 2 
(RALDH1, 2), respectively. In visceral fat, MRL.lpr mice revealed a significantly higher 
expression of the gene encoding the enzyme that produces retinaldehyde, ADH1, but a 
trend towards increasing RALDH2 as well (p=0.06) (Fig. 5a). No changes to PPAR, 
adiponectin or CD36 were observed in visceral adipose tissue (Fig. 5b). In subcutaneous 
adipose tissue, MRL.lpr showed a significantly lower expression of RALDH1, and a 
trend towards lower levels of PPAR and adiponectin (Fig. 5c-d).  
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Figure 5: Altered retinaldehyde metabolism and PPARγ signaling gene expression 
in adipose tissue of MRL.lpr mice.  Quantification by RT-PCR of genes involved in 
retinaldehyde production and breakdown, and PPAR, adiponectin (adipoQ), and CD36 
in (a-b) visceral fat and (c-d) subcutaneous fat of MRL.lpr lupus mice vs. MRL controls 
maintained on chow diet (n=6 per group; *, p<0.05). 
Analysis of gld.apoE
-/-
 mouse model of lupus and accelerated atherosclerosis.  
To determine if the results we observed in MRL.lpr mice are specific to one lupus 
model, we examined the gld.apoE
-/-
mouse model of accelerated atherosclerosis and lupus. 
After 12 weeks of Western diet, no change was observed in body weight of gld.apoE
-/- 
mice compared to the wild type controls (Fig. 6a). However, as expected, the gld.apoE
-/-
 
mice presented significantly larger lymph nodes and spleens (Fig. 6b-c). Similar to our 
observations in the MRL.lpr mice, visceral and subcutaneous fat depots had significantly 
less mass in the gld.apoE
-/-
 mice compared to wild type controls (Fig. 6d). 
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Figure 6: Body and organ weights of gld.apoE
-/-
 mice. (a) Endpoint body weight of 
gld.apoE
-/-
 vs. wild type after 12 weeks of Western diet. (b) Lymph nodes and (c) spleen 
were harvested from gld.apoE
-/-
 and wild type mice and weighed wet. (d) The visceral fat 
(VFAT) and subcutaneous fat (SUBQ) weight were collected and weighed from 
gld.apoE
-/-
 vs. wild type (n=10 per group; *, p<0.01). 
Circulating retinaldehyde levels were quantified in both wild type and gld.apoE
-/-
 
mice maintained on a chow diet or a high-cholesterol Western diet. Our data show that 
the circulating retinaldehyde levels in mice were largely influenced by Western diet (Fig. 
7). In a comparison between wild type and gld.apoE
-/-
 mice, circulating retinaldehyde did 
not change significantly, regardless of diet. However, wild type mice fed with Western 
diet had significantly higher retinaldehyde levels compared to wild type that received 
chow diet ([Rald]=6.99±0.82, 2.30±0.44nmol/µl, respectively). Similarly, retinaldehyde 
levels in gld.apoE
-/-
 mice increased with Western diet ([Rald]=2.91±0.66, 
5.43±0.71nmol/µl, respectively).  
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Figure 7: Circulating retinaldehyde (Rald) is increased by Western diet. Serum 
retinaldehyde concentration was measured by HPLC, chow diet (C57, n=16; gld.apoE
-/-
, 
n=7) vs. Western diet (C57, n=10; gld.apoE
-/-
, n=8) (*, p<0.05).  
 Since our most significant observation arose from mice maintained on Western 
diet, we continued our studies with those cohorts. We next examined the mRNA 
expression levels of genes involved in retinaldehyde synthesis and catabolism. We 
observed no change in the expression of these genes in the visceral fat of gld.apoE
-/-
 mice 
compared to wild type when maintained on Western diet (Fig. 8a). In addition, no change 
was observed to expression of PPARγ or its target genes in visceral fat of gld.apoE-/- 
compared to control (Fig. 8b). However, in subcutaneous fat, gld.apoE
-/-
 showed 
significantly less expression of the enzymes responsible for retinaldehyde metabolism as 
well as PPARγ, adiponectin, and CD36 when compared to wild type mice (Fig. 8d). 
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Figure 8: Differing expression of retinaldehyde and PPARγ genes in adipose tissue 
of wild type and gld.apoE
-/-
 mice. Quantification by RT-PCR of genes involved in 
retinaldehyde production and breakdown, and PPAR, adiponectin (adipoQ), and CD36 
in (a-b) visceral fat and (c-d) subcutaneous fat after Western diet (n=6 per group; *, 
p<0.01).  
Since the serum retinaldehyde levels in both wild type and gld.apoE
-/-
 mice 
models were affected by diet, we questioned whether these expression changes would be 
further affected by lupus and accelerated atherosclerosis. We therefore measured the 
mRNA expression of the genes in adipose tissues of gld.apoE
-/-
 fed with a chow diet 
compared to its counterpart fed with a Western diet. Analysis in visceral adipose tissue of 
mRNA levels of ADH1, trended to increase (p=0.052), while RALDH1 trended to 
decrease (Fig. 9a). Western diet resulted in significantly decreased adiponectin mRNA 
expression in visceral fat (Fig. 9b). The results for enzyme expression were slightly 
different when examined in subcutaneous fat, trending to decrease ADH1 and RALDH1, 
while RALDH2 trended to be higher (Fig. 9c). Overall, the most dramatic change to 
PPARγ and its target genes occurred in subcutaneous adipose tissue, in which we 
observed robust decreases in both PPARγ and adiponectin (Fig. 9b-d).  
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Figure 9: Western diet inhibits PPARγ signaling in gld.apoE-/- mice. Quantification 
by RT-PCR of genes involved in retinaldehyde production and breakdown, and PPAR, 
adiponectin (adipoQ), and CD36 in (a-b) visceral fat and (c-d) subcutaneous fat in a 
mouse model of accelerated atherosclerosis and lupus on chow diet vs. on Western diet 
(n=4 per group; *, p<0.05).  
 Taken together, it appears that amount of circulating retinaldehyde is not only 
affected by lupus, but also by Western diet. Changes to the components of the retinoic 
acid pathway, as well as downstream PPAR signaling can be observed in both the 
MRL.lpr mouse model of lupus and the gld.apoE
-/-
 mouse model of accelerated 
atherosclerosis and lupus. This suggests a potential pro-inflammatory role of 
retinaldehyde in lupus. 
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DISCUSSION 
 Countless scientific efforts have been devoted to the search for new therapeutic 
target of SLE from various mechanistic perspectives. The beneficial role of PPARγ 
agonist treatment has recently come to light, however, while adiponectin signaling is a 
proposed mechanism, the exact pathway to target has not been elucidated. With the link 
of metabolic syndrome and SLE recently reported, and a role for retinaldehyde in PPARγ 
signaling inhibition, the relationship between retinaldehyde and lupus pathogenesis 
should be brought to scientific attention. The main goal of our current research was to 
study the biological role of retinaldehyde in the development of SLE.  
 In order to investigate the relationship between circulating retinaldehyde level and 
SLE, we compared the serum retinaldehyde levels in a lupus mouse model (MRL.lpr) 
and its control (MRL). MRL.lpr mice showed a higher circulating retinaldehyde level 
than its control on a chow diet. In addition, MRL.lpr expressed more alcohol 
dehydrogenase (ADH1) mRNA in the visceral fat. To our surprise, circulating 
retinaldehyde levels did not differ between gld.apoE
-/-
 mice and wild type on a chow diet 
or on a Western diet. However, both gld.apoE
-/-
 and wild type on a Western diet showed 
higher serum retinaldehyde concentrations than their counterparts on a chow diet. These 
results suggest that the circulating retinaldehyde level is influenced by both lupus and 
high cholesterol Western diet.  
Interestingly, circulating retinaldehyde levels in male gld.apoE
-/- 
mice did not 
change after feeding with a Western diet (n=3 on a chow diet, n=11 on a Western diet; 
[Rald]=2.96 1.00, 4.29 0.90 nmol/μl, respectively; p=0.51) (data not shown). This 
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result suggests that there might be a sex-specific response to the high cholesterol Western 
diet in the lupus mouse model. A caveat to these results is the small number of male mice 
analyzed after chow diet. However, this is still of potential interest since there is a higher 
prevalence of SLE in females than in males, and our results could suggest a potential 
gender specific relationship between circulating retinaldehyde and SLE.  
There are several enzymes involved in the synthesis and catabolism of 
retinaldehyde as well as PPARγ signaling (Fig. 1). It has been described that retinoic acid 
is produced primarily by RALDH1 in visceral fat and by RALDH1 and RALDH3 in 
subcutaneous fat (Reichert et al., 2011). Therefore, we measured the mRNA expression 
of these enzymes in two different depots of white adipose tissues (visceral and 
subcutaneous) in order to determine which, if any, enzyme expression in this pathway is 
altered in SLE. Despite similar circulating retinaldehyde levels between gld.apoE-/- and 
wild type mice, we still observed differences in gene expression. While no change was 
observered between gld.apoE
-/-
 and wild type on a chow diet, gld.apoE
-/-
 on a Western 
diet showed a significant decrease in the mRNA expression of ADH1 in subcutaneous fat 
compared to wild type controls. A slightly larger magnitude of decrease was observed in 
RALDH1 compared with wild type on the same diet. It is interesting to note that a 
decrease of RALDH1 mRNA expression was only found in the subcutaneous fat of both 
of the lupus models (gld.apoE-/- and MRL.lpr), indicating that the enzyme expression 
may be altered in a depot-specific manner in lupus. 
An interesting observation was that RALDH2 trended to be higher in some 
instances. This would suggest that retinaldehyde could be more efficiently catabolized, 
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however, this in contrast to our observations on retinaldehyde accumulation in lupus 
models. One possibility could lend from the study demonstrating that RALDH2 is 
inefficient at retinaldehyde oxidation (Duester, 2008). Another possible explanation is 
that RALDH2 is expressed specifically in mitochondria (Kitabatake et al., 1981). It has 
been shown that T lymphocytes of proteins with SLE have a disrupted mitochondrial 
membrane potential, resulting in constant hyperpolarization (Perl et al., 2012). This 
causes a shift from apoptosis induction, to a necrosis pathway, thus, leading to 
inflammation in SLE. Therefore, it is possible that dysfunctional mitochondrial 
biogenesis under conditions of SLE may disrupt proper signaling of RALDH2, thereby 
still leading to an increased buildup of retinaldehyde. This would be an area of future 
study. 
 Exposure of wild type mice to high fat diet increases PPARγ mRNA expression in 
adipose tissues (Vidal-Puig et al., 1996). In our study, the gld.apoE-/- mice showed 
decreased PPARγ mRNA expression in subcutaneous fat, and decreased adiponectin 
mRNA expression in both visceral fat and subcutaneous fat after being fed with high-
cholesterol Western diet. Even though both gld.apoE-/- and C57 presented increased 
circulating retinaldehyde after 12 weeks of Western diet, only gld.apoE-/- had decreased 
mRNA expression of the genes involved in PPARγ signaling pathway, indicating that 
lupus models may be more vulnerable to the increased level of circulating retinaldehyde 
induced by Western diet.  
Western diet accelerated the body weight gain to a similar extent in both 
gld.apoE
-/-
 and wild type mice, but the weight gain in gld.apoE
-/-
 mice was due to 
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enlarged lymph nodes and spleens, whereas the weight gain in wild type mostly came 
from increased fat mass. It would be beneficial to subject the mice to metabolic 
phenotyping to determine the lean mass to fat mass ratio for confirmation. Both lupus 
models showed a significant less white adipose tissue mass compared with their controls, 
suggesting that adipogenesis is impaired in lupus. In addition, the white adipose tissue 
mass in gld.apoE
-/-
 mice fed Western diet trended to be lower than the gld.apoE
-/- 
fed with 
a chow diet (p=0.07). The disrupted expression of retinoic acid pathway components and 
downstream signaling targets known to be involved in adipogenesis is further evidence 
that this area of research merits future study. Potential experiments could include 
administration of high-fat/high-sucrose diet to lupus models and analysis of adipose 
tissue inflammation.  
Although adipose tissue plays a role in retinoid metabolism, and fat is the second 
largest storage site for retinoid in the body, it is important to investigate the mRNA 
expression of genes involved in retinaldehyde metabolism pathway as well as PPARγ 
signaling in the liver, given the fact that liver is the largest storage site for retinoid 
(Blomhoff et al., 1991). As we observed a significantly decreased white adipose tissue 
mass in lupus models, the contribution of the retinaldehyde metabolism enzymes in white 
adipose tissue to the circulating retinaldehyde level is questionable. It is possible that the 
lipids accumulated in the liver, rather than by the adipose tissues, contribute to the 
observed increase in circulating retinaldehyde. 
  As retinaldehyde is the sole precursor of retinoic acid, decreased expression of 
the retinaldehyde catabolizing enzymes lead to a decreased amount of retinoic acid 
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production. It has been shown that retinoic acid blocks adipogenesis by upregulating the 
expression of the adipogenesis inhibitors Pref-1, Sox9, and Kruppel-like factor 2 (Berry 
et al., 2012). Similar results have been found in RALDH1
-/-
 mice, including smaller lipid 
cell size and less lipid accumulation (Ziouzenkova et al., 2007). Our study has observed a 
higher circulating retinaldehyde level in MRL.lpr lupus model, which presented impaired 
adipogenesis compared with its control. However, whether this is a causal relationship 
requires further investigation.  
Our data suggest that there might be a strain-specific association between serum 
retinaldehyde concentration and lupus pathogenesis. There might also be a gene-diet 
interaction involved. This is an area worth further investigation, and could be extended to 
include other mouse models of lupus such as the NZB/W mouse strain, or better yet, 
examined in human serum from SLE patients and healthy controls. 
-Limitations 
 There are some limitations in our study. One major limitation regarding our diet 
comparison is that we used chow diet as a control diet for the Western diet. The plant-
derived ingredients in a chow diet show a high variability in nutrient contents (Sasidharan 
et al., 2013). Therefore, the difference between a chow diet and a high-cholesterol 
Western diet is not limited to the fat content. The chow diet used in this study contained 
15IU/g of vitamin A. Whereas the Western diet contained 10g/kg vitamin mix, which 
was composed of 3.96g/kg of 500,000IU/g vitamin A palmitate. Therefore, the vitamin A 
content in the Western diet was 19.8IU/g. The different amount of vitamin A obtained 
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from these two diets would also contribute to a differential change in the circulating 
retinaldehyde levels in our mouse models.  
More importantly, clear evidence has shown that most commercial chow diets 
contain high levels of phytoestrogens due to their soy-based ingredients that would 
influence the hormone levels, especially circulating isoflavone level, in the mouse model 
(Brown & Setchell, 2001). The prevalence of SLE differs largely between sexes, 
indicating a huge impact of sex hormones in the disease pathogenesis. Even though we 
focused on female mice in our current study, this diet choice would limit our capacity to 
expand our research on the male mice. This would also challenge our extra finding about 
the non-differential circulating retinaldehyde levels in the male gld.apoE
-/- 
mouse models 
on chow and Western diet. Therefore, the use of a chow diet as a control diet is a major 
confounding factor in our study. An ideal control diet for a high-cholesterol Western diet 
should be a semi-purified research diet with intentionally modified ingredients that only 
varies in fat content (Sasidharan et al., 2013). If chow diet had to be used, comparisons 
should only be made regarding the response of different genotypes fed with the same 
diet.   
GAPDH was used as an endogenous control gene when to measure the mRNA 
expressions of genes of interest in the adipose tissues using RT-PCR. However, it has 
been shown that GAPDH is not the best choice as its expressions vary in adipose tissues 
(Suzuki et al., 2000). 18S rRNA would be a better control due to its relatively invariant 
expression level in different tissues (Bookout & Mengelsdorf, 2003). In addition, the 
mRNA expression we observed might not be accurate information for the enzyme levels 
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in certain tissues because the mRNA may not be fully transcribed into protein. Western 
blotting could be employed for a higher accuracy in enzyme level measurement.  
We used vitamin D2 as an internal standard for retinaldehyde HPLC analysis, 
since the rodent diets we used in our study contained only vitamin D3 to meet the vitamin 
D requirement. In addition, our standard testing results suggested vitamin D2 is a better 
choice for internal standard and the ratio of the extraction efficiencies of vitamin D2 and 
retinaldehyde oxime are close to 1:1. However, since there are still some variations 
among each run, using radiolabelled tracers in each sample is a more accurate method to 
measure the recovered oxime level.  
Since we observed a significant impact of Western diet on circulating 
retinaldehyde concentrations in both gld.apoE
-/-
 and C57, as well as the mRNA 
expression of adiponectin and PPARγ in adipose tissues of gld.apoE-/-, it is important to 
distinguish whether the effects were caused by the quality or the quantity of the food 
intake. However, we did not measure the food consumption of the mice, leaving this 
question unanswered.  
-Summary 
 In conclusion, we observed a high circulating retinaldehyde level in the MRL.lpr 
lupus model. In addition, our study reveals that a high-cholesterol Western diet can 
increase circulating retinaldehyde, and this can affect PPARγ signaling on a lupus 
background. This proposal has begun to elucidate the hypothesis that retinaldehyde 
buildup in lupus is crucial to the progression of SLE and metabolic disease. In addition, 
we observe changes in PPARγ target genes in adipose tissue, which is understudied in 
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terms of signaling and adipogenesis in SLE. However, further investigation remains to 
determine the biological role of retinaldehyde in SLE. Therefore, our future proposed 
studies would allow a molecular dissection of retinaldehyde-induced inhibition of PPARγ 
signaling in adipose tissue of lupus mouse models to determine a potential therapeutic 
target to benefit SLE and its metabolic complications. 
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